Method, Device, & Software for Delivery of Anesthetic Vapor
OHSU # 1798
An anesthetic vaporizer using temperature-vapor pressure relationships of volatile anesthetics to electronically control the delivery of clinically relevant concentrations of inhalational anesthetic vapor.
Problem: Currently available variable-bypass anesthetic vaporizers require frequent calibration and maintenance, with each calibration unique to a particular anesthetic, and are heavy and slow to change concentration. This can be challenging in non-operating room circumstances such as animal research laboratories, intensive care units, medical transport, and military field environments.
In contrast, our vaporizer can contain and vaporize any agent by temperature control of the anesthetic rather than air flow. The device comprises an insulated vessel for the liquid anesthetic, a thermoelectric refrigeration system to cool the vessel, and an electronic controlling device with custom software to set the desired agent concentration and temperature using integral-derivative algorithms. Advantages of the OHSU device include:
· eliminates the need for expensive servicing and calibration;
· decreased size and weight makes it ideal in space constrained environments;
· use is not tied to any one anesthetic: can be used as a universal system for a wide variety of liquid anesthetics, and;
· use of the device is ideal for suboptimal situations such as rural clinics, confined spaces, field military use, or veterinary use.
In the North American total anesthesia and respiratory devices market for 2012, anesthesia machines represented 6.2% of the total market. This translates to a $5.703M market with a CAGR (compound annual growth rate of 4.9%. Segmenting out the United States for 2013, all anesthesia machines had a value of $357M with a volume of 6,561 units and a CAGR of 9.5%. The distribution share in 2013 was $286.6M to US hospitals and $51.1M to US laboratories.
A prototype has been developed. The temperature-vapor pressure relationship at clinical concentrations for desflurane, isoflurane, and sevoflurane at temperatures below zero degrees Celsius was tested and results established the “TMAC” (temperature minimum alveolar concentration) for the anesthetics.
US Provisional patent application filed July 29, 2013, s/n 61/859,462.
Patent rights are available for exclusive in-licensing
- Michael Hutchens, SM.Anesthesiology & Perioperative Medicine
- Nabil Alkayed, SM.Anesthesiology & Perioperative Medicine
- Henry Casson, SM.Anesthesiology & Preoperative Medicine
- Katie Schenning, SM.Anesthesiology & Preoperative Medicine
For more information, contact:
Senior Technology Development Manager